Kaiso contributes to DNA methylation-dependent silencing of tumor suppressor genes in colon cancer cell lines

EC Lopes, E Valls, ME Figueroa, A Mazur, FG Meng… - Cancer research, 2008 - AACR
EC Lopes, E Valls, ME Figueroa, A Mazur, FG Meng, G Chiosis, PW Laird, N Schreiber-Agus…
Cancer research, 2008AACR
Aberrant CpG methylation of tumor suppressor gene regulatory elements is associated with
transcriptional silencing and contributes to malignant transformation of different tissues. It is
presumed that methylated DNA sequences recruit repressor machinery to actively shutdown
gene expression. The Kaiso protein is a transcriptional repressor expressed in human and
murine colorectal tumors that can bind to methylated clusters of CpG dinucleotides. We
show here that Kaiso represses methylated tumor suppressor genes and can bind in a …
Abstract
Aberrant CpG methylation of tumor suppressor gene regulatory elements is associated with transcriptional silencing and contributes to malignant transformation of different tissues. It is presumed that methylated DNA sequences recruit repressor machinery to actively shutdown gene expression. The Kaiso protein is a transcriptional repressor expressed in human and murine colorectal tumors that can bind to methylated clusters of CpG dinucleotides. We show here that Kaiso represses methylated tumor suppressor genes and can bind in a methylation-dependent manner to the CDKN2A in human colon cancer cell lines. The contribution of Kaiso to epigenetic silencing was underlined by the fact that Kaiso depletion induced tumor suppressor gene expression without affecting DNA methylation levels. As a consequence, colon cancer cells became susceptible to cell cycle arrest and cell death mediated by chemotherapy. The data suggest that Kaiso is a methylation-dependent “opportunistic” oncogene that silences tumor suppressor genes when they become hypermethylated. Because Kaiso inactivation sensitized colon cancer cell lines to chemotherapy, it is possible that therapeutic targeting of Kaiso could improve the efficacy of current treatment regimens. [Cancer Res 2008;68(18):7258–63]
AACR